Read about our 4 hour rapid WGS collaboration!

Learn More

Broad Clinical Labs: The National Multi-Omics Accelerator

The National Multi-Omics Accelerator: How Broad Clinical Labs Provides Inclusive Access to Translational Science and Technology

For three decades, the genomics field has refined the science and methodology of sequencing. This pursuit has reached a point of maturity where the cost of a whole human genome has reached an accessible price point and throughput has scaled by orders of magnitude. The sequencer itself has transitioned from a primary variable to a reliable workhorse.

The next frontier of progress lies in everything surrounding the instrument: sample standardization, data harmonization, governance frameworks, computational infrastructure, and the organizational coordination required to run large cohorts reproducibly across dozens of sites. These are not technical problems in the traditional sense. They are systems-level, structural requirements for the integrity of population-scale science.

Broad Clinical Labs (BCL) was built to provide the governance and infrastructure necessary to address these complexities. As a wholly owned subsidiary of the Broad Institute, BCL operates not only as a leading sequencing service provider, but as a national accelerator for multi-omic science through fully integrated technologies and services specialized for spatial transcriptomics, functional genomics, proteomics, and data sciences. BCL offers an industrial-grade infrastructure partnership with a mission to make the most rigorous genomic and multi-omic methods accessible to every researcher, clinician, and biopharma organization working to advance human health.

The Genesis of Scale

BCL’s origins trace directly to the Human Genome Project and that lineage shapes the organization’s guiding principles today: that applying rigorous industrial standards and a manufacturing mindset to traditionally bench-level academic science can fundamentally transform what biology is capable of. At the time, sequencing an entire human genome seemed almost impossibly ambitious. This achievement was not the result of a single technological breakthrough, but of a commitment to a framework of standardization, automation, scale, and rigorous quality management. The Broad Institute’s role in that project established a culture and a way of working that BCL embodies today.

Twenty-five years later, BCL applies that same philosophy across the full spectrum of complex molecular biology. The goal, as Niall Lennon, Chair and Chief Scientific Officer at Broad Clinical Laboratories, LLC describes it, is to approach scientific challenges not as individual experiments but as a platform that enables thousands of studies to run consistently and reproducibly, while continuously removing variability and improving data quality. BCL is, in that sense, the operational embodiment of everything the Broad Institute has learned about what it takes to make science scale.

“Technological innovation matters, but impact comes when that technology can run reliably at population scale. At BCL, our philosophy is very much about industrializing high-quality science so it becomes accessible infrastructure for the broader field.”

Building Systems that Support Discovery

Across the national and international genomic initiatives BCL has contributed to over the past two decades, the lesson has been consistent: the hardest problems are no longer purely technological. Conducting large-scale sequencing has become a mature and standardized practice. The challenge lies in the systems that govern the sample and data lifecycles. There are current barriers to precision medicine at population scale, such as:

  • Recruiting and enrolling large numbers of clinical trial and research study participants with associated well described phenotypes and clinical metadata
  • Collecting high-quality samples using standardized procedures across the country or around the globe
  • Maintaining chain of custody
  • Ensuring harmonized, reproducible bioinformatics pipelines that produce data compatible with a range of analytical programs
  • Governing data responsibly across a complex network of sponsors, researchers, clinicians, and participants

Overcoming these system-level limitations will require coordination among leaders in science, operations, and policy—along with a purposefully built infrastructure to address them.

BCL plays a central role in designing and operationalizing this infrastructure, supporting the full lifecycle of data generation and enabling coordination across sample collection, data governance, and information flow. By integrating these systems across programs, BCL helps ensure that discovery projects, clinical research, clinical trials, and diagnostic programs are not only efficiently executed, but also connected and scalable.

Modular Innovation: Flexibility with a Focus on Quality

One of the central design challenges in large-scale genomics is balancing standardization and innovation. Standardization is essential as it allows data from thousands of samples or multiple studies to be comparable and analytically meaningful. However, the field evolves quickly so it is essential that infrastructures are built to accommodate the introduction of novel technologies and new assays without compromising data integrity.

BCL operates within a modular architecture guided by a highly visible quality management system. Core infrastructure — automation, quality control, and computational pipelines — is standardized and stable. Within that framework, individual components can be introduced, replaced, or updated in a controlled way as technologies evolve. Capabilities including spatial transcriptomics, large-scale CRISPR perturbation screens, single-cell, and long-read sequencing platforms, can be introduced into the workflow without rebuilding the entire system. Change control remains rigorous so that data comparability is preserved.

BCL’s relationship to the Broad Institute is a benefit to the broader scientific community. The Broad Institute’s research teams continuously produce and validate new methods across functional genomics, spatial biology, proteomics, and data science. BCL serves to operationalize that innovation engine at industrial-scale for greater clinical and translational impact, translating validated research methods and building the workflow rigor, automation, and quality management needed to make them accessible to scientists everywhere. Many BCL workflows operate under CLIA-certified and CAP-accredited quality management systems, and data delivery is designed for compatibility with AI and machine learning analysis pipelines through cloud infrastructure platforms like Terra, ICA, and Manifold.

“BCL’s role is to help translate breakthrough methods into platforms that can actually power clinical research reliably, reproducibly, and at scale.”

 The Responsibility of Stewardship: Protecting Data Sovereignty

The biospecimens collected by population cohorts, hospital biobanks, and disease-focused foundations represent the trust of participants — patients and families who have enrolled because they believe in the potential for scientific studies to improve lives. That trust carries obligations that BCL takes seriously at every level of the organization.

BCL is not a data company. That distinction is important in a field where data ownership, privacy, and secondary use have become increasingly scrutinized. BCL does not sell participant data, and it does not use partner data beyond what is required to perform its services. When a biopharma organization, hospital, or research institution partners with BCL to generate data, that data belongs to the partner and is returned. BCL retains only what regulatory obligations require.

This philosophy is backed by a robust data infrastructure. BCL’s data systems are NIST 800-53 compliant and designed to satisfy the information security requirements of federal, biopharma, and clinical partners. Every piece of participant information is held within a tightly regulated security boundary, auditable and defensible, to support organizations navigating the increasingly complex standards of clinical genomic data governance. BCL’s not-for-profit, partner-owned data model offers the kind of trusted stewardship that is increasingly difficult to find at scale.

Next Steps: A National Accelerator for Multi-Omic Science

Precision medicine at population scale requires a national infrastructure capable of supporting large-scale data generation, secure data sharing, and long-term stewardship of genomic and multi-omic datasets. It requires governance frameworks that enable responsible data access while sustaining public trust. And it requires partners who can translate the best methods the field has developed into platforms that run reliably and at scale.

BCL’s role is to serve as a national accelerator, making the technologies and operational expertise developed at the Broad Institute available to the entire scientific community. Over the coming year, BCL is focused on expanding access to high-quality clinical-grade multi-omics services, bringing spatial transcriptomics, functional genomics, and additional cutting-edge methods to the same level of quality as its genomics offerings. The goal is a future in which any researcher, at any institution, can access the same integrated, multi-omic data infrastructure that powers discovery at the Broad Institute.

BCL applies this same approach to scale multi-omic assays developed by academic, biopharma, and industry teams across the globe. Learn more about Broad Clinical Labs’ multi-omic services at broadclinicallabs.org.

Return to the Blog

Sean Hofherr

Chief of Clinical Strategy and Product Development, Broad Clinical Labs

Sean Hofherr is dual board certified by ABMGG in Clinical Biochemical Genetics and Clinical Molecular Genetics. Sean serves as the Chief of Clinical Strategy and Product Development at Broad Clinical Labs. In this role at BCL, Sean is able to leverage his extensive experience to guide the clinical vision and delivery across the organization. Sean most recently served as the Chief Operating Office at Fabric Genomics, which focuses on the use of AI and Bioinformatics for Clinical Interpretation of whole genome sequencing. Prior to Fabric, Sean was the Chief Scientific Officer and CLIA Director at the commercial reference laboratory, GeneDx.

Sean received his B.S. degree in Microbiology and Cell Sciences from the University of Florida before earning his Ph.D. in Molecular and Human Genetics from Baylor College of Medicine. Sean completed clinical fellowships in Clinical Biochemical Genetics and Clinical Molecular Genetics at the Mayo Clinic.

Danielle Perrin

Chief of Staff, Broad Clinical Labs

As Broad Clinical Labs’ Chief of Staff, Danielle Perrin advises and supports colleagues on the executive leadership team in BCL’s strategic planning and execution. She builds and leads new organizational functions and processes and leads critical projects, as well as driving effective information flow, decision making, and execution throughout the organization. An operations leader with a business, engineering, and biology background and 20+ years of experience in the genomics field, Perrin has a track record of driving operational excellence and building and scaling both physical and business processes. During her career at Broad, which started in 2003 at the tail end of the Human Genome Project, Perrin has led laboratory operations and R&D teams in Broad’s Genomics Platform, as well as fulfilling senior advisory and leadership roles in the Broad Institute’s COO and CFO offices.

Perrin received her B.S. in Biology and M.E. in Biotechnology Engineering from Tufts University and her M.B.A. from the MIT Sloan School of Management.

Tim De Smet

Chief Commercial Officer, Broad Clinical Labs

As Chief Commercial Officer of Broad Clinical Labs, Tim De Smet leads BCL’s business development, alliance management, external project management, and customer support teams. A Broad Institute employee since 2008, De Smet has held leadership roles and managed teams of various sizes in Broad’s Genomics Platform and clinical lab, spanning laboratory operations, finance, and informatics, and has expertise in work design, financial modeling, and high scale laboratory and business operations.

De Smet received his B.S. in Biochemistry and M.B.A. from Northeastern University.

Jim Meldrim

Chief Technology Officer, Broad Clinical Labs

As Chief Technology Officer, Jim Meldrim sets the vision for Broad Clinical Labs’ informatics systems, including the hardware and software used for sample intake and tracking, data production, analysis, and delivery. Having held a variety of laboratory and informatics-focused leadership roles at Broad, spanning R&D and production operations, Meldrim has been a leader and innovator in the generation, management, and analysis of genomic data since 1999, beginning with sequencing data generation for the Human Genome Project.

Meldrim received his B.S. in Biology from Cornell University.

Sheila Dodge

Chief Operating Officer, Broad Clinical Labs

As Chief Operating Officer, Sheila Dodge leads Broad Clinical Labs’ process development and implementation activities, as well as lab operations, financial planning and operations, quality & compliance, and core business processes. A Six Sigma Black Belt with extensive experience in process development and high throughput genomics operations, Dodge is an expert in work design and in collaborating with a range of collaborators, scientists, engineers, and technology partners to rapidly integrate new technologies and operationalize innovations. A member of the Broad Institute since 2001, Dodge is an Institute Scientist and lectures at the MIT Sloan School of Management on operations, dynamic work design, and visual management techniques.

Dodge received her B.A. in biochemistry and molecular biology from Boston University and her master’s degree in biology from Harvard University. She earned her M.B.A. from MIT Sloan School of Management.

Heidi Rehm, Ph.D., FACMG

Chief Medical Officer and Clinical Laboratory Director, Broad Clinical Labs

Heidi Rehm is board-certified by ABMGG in Clinical Molecular Genetics and Genomics and serves as BCL’s Chief Medical Officer and Clinical Laboratory Director. She oversees BCL’s regulatory requirements, leads the clinical team performing genomic interpretation and variant analysis, and guides BCL’s efforts in genomic testing for clinical and research use. She is also an Institute Member of the Broad and co-director of the Medical and Population Genetics Program. Rehm is also the Chief Genomics Officer in the Department of Medicine and Genomic Medicine Unit Director at the Center for Genomic Medicine at Massachusetts General Hospital, working to integrate genomics into medical practice. She is a principal investigator of ClinGen, providing free and publicly accessible resources to support the interpretation of genes and variants. She co-leads both the Broad Center for Mendelian Genomics, focused on discovering novel rare disease genes, and the Matchmaker Exchange, which aids in gene discovery. She is Chair of the Global Alliance for Genomics and Health, a principal investigator of the Broad-LMM-Color All of Us Genome Center, co-leader of the Genome Aggregation Database (gnomAD), and a Board Member and Vice President of Laboratory Genetics for the American College of Medical Genetics and Genomics.

Rehm received her B.A. degree in molecular biology and biochemistry from Middlebury College before earning her M.S. in biomedical science from Harvard Medical School and Ph.D. in genetics from Harvard University. She completed her post-doctoral training with David Corey in neurobiology and a fellowship in clinical molecular genetics at Harvard Medical School.

Niall Lennon, Ph.D.

Chair and Chief Scientific Officer, Broad Clinical Labs

As Chair and Chief Scientific Officer of Broad Clinical Labs, Niall Lennon leads the team and sets the scientific and clinical vision for the organization. Dr. Lennon joined the Broad Institute in 2006 and has since contributed to the development of applications for every major massively parallel sequencing platform across a range of fields. In 2013 Dr. Lennon led the effort to establish a CLIA licensed, CAP-accredited clinical laboratory at the Broad Institute to facilitate return of results to patients and to support clinical trials. More recently, he has led efforts to achieve FDA approval for large-scale genomics projects (NIH’s All of Us Research Program) and for Broad’s own clinical diagnostic for COVID-19 testing operation, which returned 37+ million results to patients. Dr. Lennon is a principal investigator of the eMerge and All of Us projects, an Institute Scientist at Broad, Associate Director of Broad’s Gerstner Center for Cancer Diagnostics, and an adjunct professor of biomedical engineering at Tufts University, where he teaches Molecular Biotechnology.

Dr. Lennon received a Ph.D. in pharmacology from University College Dublin and completed his postdoctoral studies at Harvard Medical School and Massachusetts General Hospital. He holds an executive certificate in management from the MIT Sloan School of Management.